drugset / Trial / NCT06545331
Study of XB010 in Subjects With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Timeline
- Start
- 2024-08-06
- Primary completion
- 2026-11-23
- Completion
- 2027-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | XB010 | Unknown | — | Intravenous |